Nemolizumab is an investigational humanized monoclonal antibody designed to target the interleukin-31 receptor A (IL-31RA), playing a crucial role in the pathophysiology of atopic dermatitis (AD) and prurigo nodularis.

By blocking IL-31 signaling, nemolizumab aims to alleviate the intense itching and inflammation associated with these chronic skin conditions. This drug is administered via subcutaneous injection.

Recent phase 3 trials, ARCADIA 1 and ARCADIA 2, have demonstrated the efficacy of nemolizumab in treating moderate-to-severe atopic dermatitis.

These trials involved 1,728 participants aged 12 years and older, who were inadequately controlled with topical therapies. The studies focused on the drug's ability to alleviate pruritus and improve skin lesions over a 16-week treatment period.

Both trials met their co-primary endpoints, showing that a significantly higher percentage of patients treated with nemolizumab achieved clear or almost clear skin as measured by the Investigator's Global Assessment (IGA) and at least a 75% improvement in the Eczema Area and Severity Index (EASI-75).

Participants reported significant improvements in itch severity as early as week 1 and enhancements in sleep quality by week 16. The safety profile of nemolizumab was comparable to that of the placebo group, with most adverse events being mild to moderate.

Initially developed by Chugai Pharmaceutical, nemolizumab's global marketing rights were acquired by Galderma in 2016. Galderma, the manufacturer of nemolizumab, has submitted a Biologics License Application (BLA) to the FDA based on these trial results. A decision is anticipated by the end of the year, with additional applications pending with regulatory agencies in Europe and Canada.